Leishmania Major: Transmission, Symptoms & Treatment

Leishmania major is a single-celled parasite transmitted through the bite of tiny sand flies, and it is the leading cause of “wet-type” cutaneous leishmaniasis across parts of the Middle East, North Africa, and Central Asia. The infection typically produces open, ulcerating skin sores that can persist for months before healing on their own, though they leave permanent scars. While rarely life-threatening, L. major disease affects millions of people in endemic regions, and treatment options remain limited by drug toxicity, resistance, and the absence of an approved human vaccine.

How Sand Flies Deliver the Parasite

L. major depends entirely on phlebotomine sand flies for transmission to humans. These insects are far smaller than mosquitoes, and they feed by slashing into the skin to create a tiny pool of blood rather than piercing a single vessel. During a bite, a sand fly co-injects saliva and parasites into the wound. The saliva contains roughly thirty proteins that counteract the host’s clotting response, prolonging bleeding and keeping the blood pool open long enough for the fly to feed.¹

What makes the transmission especially effective is a substance called promastigote secretory gel, or PSG. Inside the sand fly’s gut, L. major parasites secrete this sticky gel, which physically blocks the fly’s foregut. When the fly tries to take a blood meal, it has to regurgitate the gel before blood can flow in. That regurgitation deposits both the gel and a load of infectious parasites directly into the host’s skin.² The gel is not just a vehicle for delivery. In mouse experiments, PSG worsened skin infections, increased the chance of a visible lesion developing, and accelerated parasite growth. The effect was observed with gel from both L. major and a related species, L. tropica, suggesting that it is an evolutionarily conserved trick the parasite uses across different host-vector combinations.³

Wild Rodents Keep the Cycle Going

L. major is a zoonotic parasite, meaning its primary hosts are animals rather than people. For over a century, wild gerbils in the family Muridae have been recognized as the main reservoir, with Phlebotomus papatasi sand flies shuttling the parasite between rodents and occasionally to humans.⁴ In North Africa, several gerbil species carry the infection. The fat sand rat (Psammomys obesus) is one of the best studied: a 21-month field survey in Tunisia found that L. major prevalence in these rodents followed a strong seasonal pattern, peaking at about 70% in late summer before dropping to zero the following spring.⁵ Another reservoir species, Meriones shawi, can carry the infection without showing any symptoms, which makes it a silent source of parasites for local sand fly populations.⁶

This reservoir-vector cycle has practical consequences. Human outbreaks tend to track rodent population booms and sand fly seasons rather than person-to-person spread. You cannot catch L. major from another person’s lesion through casual contact. Instead, your risk depends on how close you live to active rodent colonies and how much sand fly exposure you get during the warm months when transmission peaks.

What Happens Inside the Body

Once deposited in the skin, L. major parasites are quickly taken up by macrophages, the immune cells whose job is to engulf and destroy foreign invaders. The twist is that Leishmania has evolved to survive inside these very cells. The parasite converts to a different form and replicates within compartments inside the macrophage. Research has shown that L. major’s ability to persist intracellularly depends partly on scavenging nutrients from the surrounding tissue, including sugars found in the structural matrix between cells.⁷

Whether the infection resolves or worsens depends heavily on how the immune system responds. Studies in mice during the 1980s established that a Th1-type immune response, driven by the signaling molecule interferon-gamma, activates macrophages to kill the parasites they harbor. A Th2-type response, by contrast, suppresses that killing activity and allows the infection to progress.⁸ This finding became one of the most cited examples in immunology. In reality, human immune responses are messier than the clean Th1/Th2 split seen in laboratory mice, but the core principle holds: a strong cell-mediated immune reaction is what eventually clears L. major in most people.⁹

Symptoms and the Typical Course of Disease

L. major causes what is called “wet-type” cutaneous leishmaniasis. After an incubation period of less than two months, a small red bump appears at the bite site and gradually enlarges into an open, weeping ulcer. These sores are sometimes called “oriental sores” or “tropical sores” in older literature. In most cases, lesions heal on their own within about six months, which is faster than the dry-type disease caused by the related species L. tropica. But even after healing, a depressed scar remains.¹⁰

Lesions tend to appear on exposed parts of the body: faces, hands, arms, and legs. People can develop a single sore or multiple ones depending on how many infective bites they received. The disease does not spread internally in people with healthy immune systems, which distinguishes it from visceral leishmaniasis caused by other Leishmania species. Still, “just a skin disease” vastly underestimates the experience. The sores are painful, prone to secondary bacterial infection, and can take months to close. In children and young adults whose sores appear on the face, the cosmetic damage can be devastating.

Diagnosis Beyond the Microscope

The traditional way to diagnose cutaneous leishmaniasis is to take a tissue sample from the edge of the lesion, smear it on a slide, stain it, and look for parasites under a microscope. This approach is cheap and widely available in endemic settings, but it misses a substantial number of infections. In one large comparison study, microscopy alone caught about 74% of confirmed cases, and adding parasite culture raised the combined sensitivity to roughly 83%.¹¹ A separate study in Morocco found even lower numbers, with microscopy detecting only 43% of true positives.¹²

PCR-based tests have dramatically improved accuracy. A kinetoplast DNA PCR test achieved close to 99% sensitivity in one head-to-head comparison, correctly identifying nearly all confirmed positive samples.¹¹ Quantitative PCR methods are especially valuable because they pick up infections with low parasite loads that Giemsa-stained smears miss entirely. In a study comparing the two approaches on over 400 samples, every case caught by microscopy was also caught by PCR, but the PCR identified an additional 65 cases that microscopy missed.¹³ Certain PCR methods also allow species identification, which matters for treatment decisions since different Leishmania species respond differently to drugs.

Treatment Options

Because L. major lesions eventually self-heal, the decision to treat is partly about accelerating closure, reducing scarring, and preventing secondary complications. Treatment is generally recommended for lesions on the face, large or multiple lesions, or sores that have persisted beyond a few months without improvement.

Pentavalent antimonial compounds, specifically sodium stibogluconate and meglumine antimoniate, have been the backbone of leishmaniasis treatment for decades. When injected directly into the lesion, both drugs produce complete healing in roughly 88-91% of cases within three months, with no significant difference between them.¹⁴ Intralesional injection keeps systemic side effects low, but when given systemically for more extensive disease, antimonials can cause serious toxicity including heart rhythm disturbances and liver inflammation. Resistance is also a growing concern, particularly in regions with heavy use.¹⁵

Cryotherapy, where liquid nitrogen is applied directly to the lesion, offers a drug-free alternative. In one trial, about 84% of lesions healed after one to four weekly sessions, with the remaining cases needing a few additional rounds. Side effects were mild, and scarring was often minimal.¹⁶ Response depends on lesion size and location, with smaller sores clearing faster.

Beyond these mainstays, miltefosine (an oral drug originally developed as a cancer treatment) and paromomycin (a topical antibiotic) have shown activity against L. major. In mouse experiments, combining topical paromomycin with oral miltefosine shrank lesions, healed ulcers completely, and reduced parasite loads in distant organs more effectively than either drug alone.¹⁷ Clinical use of these alternatives varies by country and availability.

Drug Resistance and Why It Matters

Antimonial drugs have been used against leishmaniasis for more than sixty years, and the mechanisms behind both their action and resistance were only clarified relatively recently. Resistance involves changes in how the parasite metabolizes the drug, alterations in thiol-based detoxification pathways, and active pumping of the drug out of the parasite cell.¹⁸ This is a particular problem in regions where incomplete treatment courses or self-medication are common, since sub-therapeutic drug exposure is exactly the kind of pressure that selects for resistant parasites. The limited drug pipeline for leishmaniasis compared to diseases of wealthier populations means that losing efficacy of existing drugs has outsized consequences.

Controlling Transmission at the Source

Since L. major cycles between rodents and sand flies before occasionally spilling over to humans, one logical approach to prevention is breaking that cycle. Rodent control programs have shown real results. In Iran, a study found that a one-year interruption of rodent control efforts led to two subsequent years of increased cutaneous leishmaniasis incidence, while restarting the program brought case numbers back down.¹⁹

A different strategy tested in Israel used fipronil-laced bait placed at the burrows of Psammomys obesus along the perimeter of a town. The treatment did not reduce sand fly numbers, but it significantly lowered the proportion of sand flies carrying L. major, effectively interrupting the rodent-to-fly transmission step without needing to eliminate every rodent or every fly.²⁰ Personal protection measures like insecticide-treated bed nets, window screens, and avoiding outdoor exposure at dusk and dawn also help, since sand flies are most active during those hours.

Climate and Geography Shape Outbreaks

The distribution of L. major is not random. It tracks closely with the conditions that favor both sand fly breeding and rodent habitat. Studies in Iran have found that warmer average temperatures, higher humidity, and lower elevation all correlate with more cases. Agricultural land cover and urban settings were strong independent predictors of outbreaks, likely because irrigation and construction create the disturbed soil and moisture that sand flies need to breed.²¹ Higher wind speeds and greater vegetation cover appeared protective, presumably because strong winds disrupt sand fly flight and dense plant cover may reduce the open ground rodents prefer.²²

These associations raise concerns about climate change. As arid and semi-arid zones expand and temperatures rise, sand fly habitat is expected to shift into regions that were previously too cool or too dry to support transmission. Urbanization at the edges of desert areas already brings human populations into closer contact with rodent reservoirs, and new irrigation projects can create fresh breeding sites for sand flies almost overnight.

The Search for a Vaccine

An old practice called leishmanization, which involved deliberately infecting a person with live L. major to produce a controlled sore and subsequent immunity, actually worked well in several countries. It was eventually abandoned because it occasionally caused persistent lesions and was impractical to standardize. Vaccine researchers have tried a range of approaches since then, including killed parasites, recombinant proteins, and DNA-based vaccines, but human trials have repeatedly struggled to produce durable protection.²³

One of the more promising recent candidates is a genetically modified L. major strain called LmCen⁻/⁻, created using CRISPR gene editing. This strain has a key gene (centrin) knocked out, which prevents it from replicating inside host cells but still allows it to trigger a robust immune response. In mice, LmCen⁻/⁻ vaccination produced protection comparable to traditional leishmanization, with no visible lesions after challenge with sand fly-transmitted L. major. The strain also appeared safe in immunocompromised mice, which was one of the main concerns with old-style leishmanization. Because it carries no antibiotic resistance marker, it is considered a viable candidate for human clinical trials.²⁴

Coinfections That Change the Game

In many regions where L. major circulates, people are simultaneously infected with intestinal worms or other parasites. This matters because helminth infections tend to push the immune system toward a Th2 response, the very response profile that favors Leishmania survival. Experimental coinfection studies in mice show that an established schistosome infection impairs the body’s ability to control Leishmania growth.²⁵ In human patients with American tegumentary leishmaniasis, those with intestinal helminth coinfections developed mucosal lesions more often, took longer to heal, and had higher rates of treatment failure or relapse compared to patients without worms.²⁶ This suggests that screening and treating intestinal parasites in leishmaniasis patients could improve outcomes, though this is rarely part of standard care.

How Skin Bacteria Influence Healing

The open sores caused by L. major do not exist in a microbiological vacuum. Research in the past decade has revealed that Leishmania infection reshapes the community of bacteria living on the skin in ways that actively worsen inflammation and delay healing. Lesioned skin shows increases in bacterial families like Staphylococcaceae and Streptococcaceae, along with decreases in normally abundant protective bacteria.²⁷ This dysbiotic skin microbiome is not just a bystander. Mouse studies showed that the altered bacterial community itself promotes inflammation, meaning the microbiome shift is both a consequence and an amplifier of the disease.²⁸

A multiomic study of human lesions found that high levels of Staphylococcus aureus in particular were associated with slower healing and elevated expression of a key inflammatory signal called IL-1β. When researchers blocked that signal in mice colonized with S. aureus and infected with Leishmania, inflammation and tissue damage dropped significantly.²⁹ This line of research is still early, but it opens the door to “host-directed” therapies where managing the skin bacteria could become part of the treatment strategy alongside antiparasitic drugs.

The Stigma That Outlasts the Infection

The permanent scars left by L. major lesions carry a social cost that is often invisible in clinical discussions. A systematic review of stigma associated with cutaneous leishmaniasis found that people living with visible lesions face misconceptions (commonly being seen as unclean or contagious), negative emotions from others including disgust, and discriminatory behavior that can affect employment, education, and relationships.³⁰ Qualitative interviews with patients revealed that self-stigma, where the person internalizes these negative views, was severe. People described isolating themselves out of fear of social exclusion, with significant damage to mental health and quality of life.³¹ Among high school students in Morocco, a population acutely sensitive to appearance, scars from earlier leishmaniasis episodes contributed to both self-stigma and social stigma along with measurable psychological effects.³² This burden lands disproportionately on women and girls in cultures where skin appearance carries heavier social weight, adding a gender dimension to what is already classified as a neglected tropical disease.